Dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer

Journal of Urology

Volumn 191, Issue 1, 2014, Pages 227-234

  Yasumizu, Yota ^a   Miyajima, Akira ^a   Kosaka, Takeo ^a   Miyazaki, Yasumasa ^a   Kikuchi, Eiji ^a   Oya, Mototsugu ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

dactolisib; docetaxel; drug resistance; prostate; prostatic neoplasms

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; ANDROGEN; DOCETAXEL; KI 67 ANTIGEN; PROTEIN KINASE B; S6 KINASE; DACTOLISIB;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER RESISTANCE; CASTRATION RESISTANT PROSTATE CANCER; CELL ASSAY; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SENSITIZATION; ENZYME PHOSPHORYLATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MALE; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT; UPREGULATION; ANIMAL TISSUE; CANCER GROWTH; CELL PROLIFERATION ASSAY;

CASTRATION RESISTANT PROSTATE CANCER; CRPC; DACTOLISIB; DOCETAXEL; DRUG RESISTANCE; MAMMALIAN TARGET OF RAPAMYCIN; MAPK; MITOGEN-ACTIVATED PROTEIN KINASE; MTOR; MTOR COMPLEX; MTORC; P; PBS; PHOSPHATE BUFFERED SALINE; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHORYLATED; PI3K; PROSTATE; PROSTATIC NEOPLASMS; S6; S6 RIBOSOMAL PROTEIN;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; HUMANS; IMIDAZOLES; MALE; MICE; MICE, INBRED BALB C; ORCHIECTOMY; PHOSPHATIDYLINOSITOL 3-KINASES; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; QUINOLINES; TAXOIDS; TOR SERINE-THREONINE KINASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84890125270     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2013.07.101     Document Type: Article

References (29)

1. W.J. Catalona Management of cancer of the prostate N Engl J Med 331 1994 996
2. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2012 CA Cancer J Clin 62 2012 10
3. H. Van Poppel, and L. Klotz Gonadotropin-releasing hormone: an update review of the antagonists versus agonists Int J Urol 19 2012 594
4. C.J. Ryan, M.R. Smith, and J.S. de Bono Abiraterone in metastatic prostate cancer without previous chemotherapy N Engl J Med 368 2013 138
5. H.I. Scher, K. Fizazi, and F. Saad Increased survival with enzalutamide in prostate cancer after chemotherapy N Engl J Med 367 2012 1187
6. J.S. de Bono, C.J. Logothetis, and A. Molina Abiraterone and increased survival in metastatic prostate cancer N Engl J Med 364 2011 1995
7. K.D. Courtney, R.B. Corcoran, and J.A. Engelman The PI3K pathway as drug target in human cancer J Clin Oncol 28 2010 1075
8. P. Liu, H. Cheng, and T.M. Roberts Targeting the phosphoinositide 3-kinase pathway in cancer Nat Rev Drug Discov 8 2009 627
9. S.S. El Sheikh, H.M. Romanska, and P. Abel Predictive value of PTEN and AR coexpression of sustained responsiveness to hormonal therapy in prostate cancer - a pilot study Neoplasia 10 2008 949
10. A.H. Reid, G. Attard, and L. Ambroisine Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer Br J Cancer 102 2010 678
11. L. Wu, D.C. Birle, and I.F. Tannock Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts Cancer Res 65 2005 2825
12. P.K. Majumder, P.G. Febbo, and R. Bikoff mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways Nat Med 10 2004 594
13. R.J. Amato, J. Jac, and T. Mohammad Pilot study of rapamycin in patients with hormone-refractory prostate cancer Clin Genitourin Cancer 6 2008 97
14. A. Carracedo, L. Ma, and J. Teruya-Feldstein Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer J Clin Invest 118 2008 3065
15. K.E. O'Reilly, F. Rojo, and Q.B. She mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt Cancer Res 66 2006 1500
16. D.D. Sarbassov, D.A. Guertin, and S.M. Ali Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex Science 307 2005 1098
17. V. Serra, B. Markman, and M. Scaltriti NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations Cancer Res 68 2008 8022
18. T. Kosaka, A. Miyajima, and S. Shirotake Long-term androgen ablation and docetaxel up-regulate phosphorylated Akt in castration resistant prostate cancer J Urol 185 2011 2376
19. M. Hasegawa, A. Miyajima, and T. Kosaka Low-dose docetaxel enhances the sensitivity of S-1 in a xenograft model of human castration resistant prostate cancer Int J Cancer 130 2012 431
20. J.A. Engelman, J. Luo, and L.C. Cantley The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism Nat Rev Genet 7 2006 606
21. C.W. Kinkade, M. Castillo-Martin, and A. Puzio-Kuter Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model J Clin Invest 118 2008 3051
22. P. Makhov, K. Golovine, and A. Kutikov Modulation of Akt/mTOR signaling overcomes sunitinib resistance in renal and prostate cancer cells Mol Cancer Ther 11 2012 1510
23. B.S. Carver, C. Chapinski, and J. Wongvipat Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer Cancer Cell 19 2011 575
24. A. Dubrovska, J. Elliott, and R.J. Salamone Combination therapy targeting both tumor-initiating and differentiated cell populations in prostate carcinoma Clin Cancer Res 16 2010 5692
25. C.X. Xu, Y. Li, and P. Yue The combination of RAD001 and NVP-BEZ235 exerts synergistic anticancer activity against non-small cell lung cancer in vitro and in vivo PLoS One 6 2011 e20899
26. J. Sunayama, K. Matsuda, and A. Sato Crosstalk between the PI3K/mTOR and MEK/ERK pathways involved in the maintenance of self-renewal and tumorigenicity of glioblastoma stem-like cells Stem Cells 28 2010 1930
27. K. Shoji, K. Oda, and T. Kashiyama Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas PLoS One 7 2012 e37431
28. S.M. Brachmann, I. Hofmann, and C. Schnell Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells Proc Natl Acad Sci U S A 106 2009 22299
29. N. Jin, T. Jiang, and D.M. Rosen Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer Clin Cancer Res 17 2011 6482